{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-070914","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2024-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.035842+00:00","generated_at":"2026-06-01T04:48:16.433276+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cara Therapeutics discontinues NP program after oral difelikefalin fails Part A of KOURAGE-1 study","bullets":["Oral difelikefalin did not demonstrate meaningful clinical benefit at any dose vs. placebo in Part A of KOURAGE-1 study for notalgia paresthetica.","Company discontinues clinical program in NP and will explore strategic alternatives to maximize shareholder value.","Cash, cash equivalents, and marketable securities were approximately $70 million as of March 31, 2024.","Drug was well tolerated; safety profile similar to prior trials. Part A enrolled 214 patients across four arms."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-070914","json":"https://secwatch.observer/filing/0001104659-24-070914.json","markdown":"https://secwatch.observer/filing/0001104659-24-070914.md","text":"https://secwatch.observer/filing/0001104659-24-070914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924070914/0001104659-24-070914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924070914/tm2416682d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:48:16.433276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}